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Systems approaches to coronavirus pathogenesis
Alexandra Scha¨fer1, Ralph S Baric1 and Martin T Ferris2Coronaviruses comprise a large group of emergent human and
animal pathogens, including the highly pathogenic SARS-CoV
and MERS-CoV strains that cause significant morbidity and
mortality in infected individuals, especially the elderly. As
emergent viruses may cause episodic outbreaks of disease
over time, human samples are limited. Systems biology and
genetic technologies maximize opportunities for identifying
critical host and viral genetic factors that regulate susceptibility
and virus-induced disease severity. These approaches provide
discovery platforms that highlight and allow targeted
confirmation of critical targets for prophylactics and
therapeutics, especially critical in an outbreak setting. Although
poorly understood, it has long been recognized that host
regulation of virus-associated disease severity is multigenic.
The advent of systems genetic and biology resources provides
new opportunities for deconvoluting the complex genetic
interactions and expression networks that regulate pathogenic
or protective host response patterns following virus infection.
Using SARS-CoV as a model, dynamic transcriptional network
changes and disease-associated phenotypes have been
identified in different genetic backgrounds, leading to the
promise of population-wide discovery of the underpinnings of
Coronavirus pathogenesis.
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Introduction
Severe Acute Respiratory Syndrome Coronavirus (SARS-
CoV) emerged in Guangdong province, China, in 2002,
causing a global epidemic that resulted in about 8000
reported cases and an overall mortality rate of 10% [1].
The virus was initially present in horseshoe bat popu-
lations, and either evolved mutations that allowed tran-
sition to Palm Civets and Raccoon Dogs before emergingin human populations, or was directly transmitted from
bats to humans and subsequently amplified through
intermediate hosts [2–4]. From there, SARS-CoV rapidly
spread across the globe, with focal outbreaks in China,
Singapore, Vietnam, Taiwan and Canada [1]. More
recently, the antigenically distinct Middle East Respir-
atory Syndrome (MERS-CoV) emerged in 2012 and is still
currently circulating in animal and human populations in
the Middle East, resulting in 184 cases and 80 deaths to
date (http://www.promed.org). MERS-CoV most likely
emerged from circulating bat strains and appears to also
replicate efficiently in camels [5,6]. Both pathogens cause
a respiratory disease, with many severely impacted indi-
viduals transitioning into an acute respiratory distress
syndrome (ARDS) [7–10]. Although the SARS-CoV out-
break was controlled by epidemiological measures, the
recent identification of SARS-like bat-CoVs that can
recognize human angiotensin 1 converting enzyme 2
receptors and replicate efficiently in primate cells docu-
ments the inevitability of a SARS-CoV-like virus re-
emergence event in the near future [11]. Together, these
data highlight prototypical outbreak concerns for the 21st
century, where increased travel and community pressures
on wildlife areas present numerous opportunities for
novel viral disease emergence followed by rapid spread
worldwide, sometimes within a matter of months [12–14].
Rapid response platforms are clearly needed to maximize
public health preparedness against emerging viruses.
A fundamental problem in dealing with emerging infec-
tious disease control is both the limited accessibility to
and the limited number of biological samples associated
with an expanding epidemic, confounding insights into
susceptibility and mechanistic disease processes which
are critical for rational antiviral and vaccine design strat-
egies. In order to advance our understanding of those
disease processes at work, novel approaches have been
evolved that utilize newly developed state-of-the-art
techniques and technologies. Systems biology [15] uti-
lizes an integration of traditional pathogenesis
approaches, as well as high-throughput molecular profil-
ing, and computational modeling to identify key host
genes and pathways involved in pathogenesis. In a related
way [16], systems genetics integrates molecular profiling
and pathogenesis readouts within genetically complex
populations to identify genes and pathways that contrib-
ute to disease variation across genetically diverse popu-
lations. Integration of both platforms provides
unparalleled power in identifying and studying host
susceptibility networks that contribute to disease out-
comes. The common feature of both discovery platforms
is that they seek to understand viral disease as part of
complex, interacting systems with multiple genes and 
response pathways. While fundamentally different from 
standard reductionist strategies, these approaches still 
rely on standard genetic, molecular biology, biochemical 
and immunologic strategies to validate the role of tar-
geted genes and networks in disease processes. Using 
these approaches, there is hope that model systems and 
platform approaches can be utilized to identify critical 
regulators of disease across genetically diverse human 
populations, and to transition these findings into prophy-
lactic and therapeutic drugs.
Systems biology approaches
Over the past decade, a series of important technological 
advances, genome wide molecular screening platforms 
and computational strategies have emerged that provide 
new opportunities for rapid response against newly emer-
ging viral disease threats, globally. The paradigm of these 
systems biology approaches [15,17] is that (Figure 1) a 
model system or systems (e.g. tissue culture model, in 
vivo animal model, or even human challenge model and 
vaccine studies) are perturbed, in our case by viral chal-
lenge, preferably resulting in a spectra of disease seve-
rities (e.g., lethal vs sub-lethal) to maximize contrast for 
downstream data mining and modeling. Over a time 
course, multiple global measures of the system’s perform-
ance are taken in response to infection, including high-
throughput molecular measures (transcriptome, pro-
teome, metabolome, etc.), as well as a variety of virologic, 
immunologic and pathologic measures (e.g. weight loss, 
respiratory function, inflammatory response, mortality 
and histopathological damage). A variety of computation 
methodologies ([18,19,20,21] and reviewed more fully 
in [22]) and network approaches are then used to de novo 
identify regulatory networks, with these networks and 
their kinetic responses then being correlated to different 
disease outcomes in the system. Following these initial 
descriptions, there are a series of continuing cycles of 
testing and perturbations (host gene knockout, virus 
mutant or therapeutic intervention) designed to further 
validate and then refine the model and to elucidate the 
mechanistic underpinnings of the systems’ performance 
as a function of infection and disease severity.
Modeling algorithms are rapidly evolving in response to 
the emergence of these complex and comprehensive 
systems wide datasets and are beyond the focus of this 
review (but see [22] for more information); however, 
many of these approaches de novo assemble the networks, 
independent of annotated pathways or interactions. By 
allowing this de novo assembly within the context of 
infection, new relationships between genes (or the break-
ing of previously annotated relationships) emerge that 
allow for the identification of critical subnetworks. Such a 
method was recently successfully used to identify critical 
components of SARS-CoV induced pathogenesis follow-
ing infection of mice [20]. A de novo assembled networkapproach was used to identify Serpine1 and other members
of the Urokinase pathway as high priority candidates in
regulating severe disease outcomes following lethal vs sub-
lethal infections. Subsequent study of Serpine1 knockouts
as well as knockouts from other pathway members con-
firmed a protective role for these Urokinase pathway
members in regulating severe SARS-CoV disease out-
comes. Illustrating the power of these de novo compu-
tational algorithms, it seems unlikely that this pathway
would have been otherwise implicated in SARS-CoV in-
fection. These approaches can become even more power-
ful by integrating analyses across multiple large-scale
datasets. Gibbs et al. [19] were able to further refine these
approaches by independently assembling transcriptional
and proteomic networks and then cross-contrasting these
two network types. This method was able to clarify net-
work membership and connections, as well as enhance the
relationship between these joint networks and aspects of
SARS-induced lung pathology. In addition, such
approaches also resulted in highly prioritized list of reg-
ulators with conserved behavior for SARS-CoV and influ-
enza A viruses (IAV) via a combined analyses, which
provide valuable candidates for downstream experimental
validations and therapeutic intervention [21].
Iterative rounds of perturbation are another key com-
ponent of the systems biology paradigm. These iterative
perturbations are utilized in order to refine and re-evalu-
ate networks when key members of these networks are
modified. While perturbations are typically thought of as
host perturbations, in some cases they can also be viral
perturbations. In this way, SARS-CoV ORF6 [23] was
identified as a key inhibitor of multiple antiviral cell
intrinsic host genetic responses by blocking the import
of targeted clusters of transcription factors into the
nucleus during infection and thereby reprogramming host
response networks following infection. Chromosome
immunoprecipitation studies further validated the role
of ORF6 expression in the nuclear import and DNA
binding of select transcription factors, and loss of
ORF6 attenuated virus pathogenesis. In a parallel
example, the SARS-CoV E protein is a known virulence
determinant [24]. Using systems biology, E protein was
found to suppress the expression of 25 stress related
proteins and specifically down-regulated the inositol-
requiring enzyme 1 (IRE-1) signaling pathway of
unfolded protein responses. In the absence of E protein,
an increase in stress responses and the reduction of
inflammation likely contributed to the attenuation of
rSARS-CoV-DE, validating the systems wide predictions.
In other cases, contrasting SARS-CoV with immune
stimulatory molecules (e.g. interferon stimulation) or
different pathogens can be used for cross-comparison.
In this way, Danesh et al. [25] were able to show that
in contrast to a strict interferon response in a ferret model
of SARS-CoV infection, a wider variety of cell migratory
and inflammatory genes were induced.
Figure 1
(a) (b)
(c)
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The Systems Biology Paradigm. Systems Biology focuses on an iterative cycle of experiments. In model system (a) mouse is infected. (b)
Measurements of molecular (e.g. whole transcriptome, proteome) and disease related phenotypes (histopathology and flow cytometry) are taken at
multiple timepoints and contrasted with mock infected animals. (c) Transcriptional (or proteomic) data are assembled into networks of interacting and
coexpressed transcripts. These networks are then correlated back to specific disease pathologies. These data are then fed into new sets of
experiments where key members of networks (e.g. the blue gene central to the network) are then disrupted to alter pathologic outcomes in a predicted
manner.Population-wide variation in coronavirus
responses
Population-wide variation in disease responses is known
to occur for many pathogens, and there was notable
variability within the disease severity and clinical out-
comes after SARS-CoV and MERS-CoV infections, most
notably in the elderly population. For SARS-CoV, sys-
tems approaches were used to differentiate resolution
from fatality in a patient cohort [26]. This study showed
that although initial immune responses were fairly
uniform, fatal cases of SARS-CoV infection exhibited
aberrant interferon stimulation, persistent chemokine
responses and disregulated adaptive immune networks.
Similarly, MERS-CoV infections have mostly clustered in
men, and those with underlying medical conditions,although this may represent a gender difference in acces-
sibility to health care in the Middle East [9]. However, as
is often the case with heterogeneous human populations,
while clear trends can be observed in disease responses, it
is unclear whether those observed differentiating patho-
logic/response classes are due to underlying genetic vari-
ation within the population, or due to other factors, such
as environmental factors, demography or exposure
histories. For example, SARS-CoV exhibited a 10%
mortality throughout the outbreak, but this mortality rate
rose to 50% in the aged population [1,12]. A mouse
model of this phenomenon suggested a genetic link, in
that increased disease severity correlates with aberrant
PGD(2) expression that impairs respiratory DC migration
and associated reduced T cell responses [27].
However, in the human population, the extent to which 
this disease variation is due to genetic versus non-
genetic causes remains unclear. It is clear from studies 
following the SARS-CoV outbreak that host genetic 
variants do have significant associations with variant 
immune phenotypes following SARS-CoV infection, 
although the clinical relevance of these polymorphisms 
and their connections to pathologic outcomes are less 
understood [28–31]. More generally, it is well accepted 
that host genetic variants play key roles in onset, 
severity and resolution of viral infection (reviewed in 
[32]). Despite the presence of several well-known and 
highly penetrant susceptibility genes of large effect 
(e.g. CCR5 and HIV [33], FUT2 in norovirus and 
perhaps rotavirus infections [34,35]), there is an increas-
ing awareness that responses to viral pathogens are 
likely regulated by complex interactions involving 
multiple variant genes and their corresponding expres-
sion networks that are activated following infection 
[36]. However, identification of these polymorphic 
genes and their associated pathways and outcomes is 
confounded by the large controlled cohorts typically 
needed to detect moderate to small effect alleles in 
association studies [37]. Therefore, novel approaches 
are needed to aid in the discovery of those polymorphic 
networks which contribute to viral pathogenesis in the 
cases of emerging pathogens with limited human 
samples
Systems genetics approaches
While genome wide association studies within human 
populations can provide powerful insight into disease 
responses, both the absence of large human cohorts to 
conduct such association studies, and the difficulty in 
transitioning such associations into mechanisms of patho-
logic or protective outcomes provide roadblocks for direct 
human studies. In answer to such needs, systems genetics 
approaches utilize genetically diverse experimental 
models to recapitulate the population-wide variation seen 
across the human population and attempt to disentangle 
complex traits, such as immune responses [38,39]. Specifi-
cally, by integrating not only pathologic and high-
throughput molecular data, but also explicit information 
on the genetic composition of the experimental popu-
lation, systems genetics seeks to identify genes and path-
ways of polymorphic genes that directly contribute to 
variation in responses to infection across genetically 
diverse populations, as well as for to further disentangle 
the underlying molecular signatures and pathways associ-
ated with various disease outcomes (Figure 2). Further-
more, by explicitly contrasting the high-throughput 
molecular and phenotypic data across unique genetic 
backgrounds, robust virus-response signatures can be 
identified across host genetic backgrounds, attaining a 
better resolution of the dynamic and host regulatory 
responses that act in host-genetic background specific 
manners during infection.The field of viral pathogenesis has long used a limited
number of mouse strains for in vivo pathogenesis studies
[40,41]. These lines (e.g. C57Bl/6J or Balb/cJ) have
played critical roles in the development of animal models
and reagents that are useful for the study of host
responses; however, they do not recapitulate the genetic
variation present within the outbred human population,
which is critical to disease responses. Recently, newly
developed mouse resources were explicitly designed for
systems genetics analysis as well as better capturing the
genetic variation seen within human populations. Specifi-
cally the Collaborative Cross (CC) [42] recombinant
inbred panel and Diversity Outbred (DO) [43] population
are novel mouse resources which combine the utility of
experimental mouse models with the genetic variability
critical to contrasting experimental models with human
responses. The CC and DO are complimentary resources
(Figure 3) with levels of natural genetic variation roughly
consistent with common variants segregating across the
human population (107 single nucleotide polymorph-
isms and 106 small insertion/deletions), and character-
ized by relatively uniform distributions of variation across
the genome. The large number of CC lines, and the
continual generation of novel genomes of DO mice give
rise to an incredibly large number of combinations of
genetic variants across those genomes. These attributes
are critical for first, mapping of genetic variants associated
with infectious outcomes, second, creating novel genetic
background with which to study transcriptional and regu-
latory networks, third, describing new models of virus
diseases and pathologies, and fourth, accurate modeling
of the human population’s genetic composition while
maintaining experimentally tractable systems [44].
Importantly for systems genetics approaches, the CC
and the DO not only facilitate initial discovery, but by
allowing for the generation of new crosses and animals
with similar allele frequencies but in new combinations,
they also allow for the validation of the role of specific
polymorphic genes and further mechanistic study
(Figure 3).
Systems genetics approaches have been used extensively
in studying the responses to influenza [44–46,47]. Over-
all, these studies have found that multiple host poly-
morphisms contribute to differential disease outcomes
following influenza infection, that some of these poly-
morphisms act in virus strain-specific manners, and that
different subsets of transcripts associate with specific
disease responses following these infections. Further-
more, by integrating these systems genetics approaches
throughout multiple timepoints, Nedelko et al. [47]
were able to show that polymorphisms worked at specific
points throughout the infection process, pointing to
further complexity in the role of genetic regulation under-
lying differential disease outcomes. Together, these stu-
dies highlight the incredible power and precision that
systems genetics approaches can provide, especially when
Figure 2
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Systems Genetics integrates systems biology and genetic complexity. Here sets of genetically well-defined yet distinct mouse strains (a) are
challenged with a pathogen and a variety (b) of disease and molecular phenotypes are collected. Integration of genetic variants within this population
and disease phenotypes (c) can identify host genome regions containing polymorphisms controlling disease phenotypes (QTL mapping), and
contrasting the expression profiles of individuals with variant polymorphisms at this loci can identify those groups of transcripts that are up-regulated
(orange) or down-regulated (purple) due to polymorphisms at this genome location, highlighting mechanisms of virus induced pathology. Furthermore,
by contrasting in a strain-specific manner all of those transcripts that are differentially expressed during infection (d), specific transcriptional subsets
can be associated with variant disease outcomes. Here each of the three mouse strains have a pool of differentially expressed transcripts (colored
circles) following infection. Therefore, the union of red, blue and green describes those transcripts commonly differentially regulated across all
genotypes in response to infection. Similarly, the intersection of red and blue transcripts (excluding green transcripts) describes those transcripts
differentially regulated in genotypes with severe lung pathologies.blended with systems biology and computational
modeling.
Systems approaches have classically used traditional tran-
scriptome profiling, such as microarray and mRNA seq.
However, there is increasing evidence that non-coding
RNAs play roles in regulating immune responses [48,49],
and can have direct impact on viral infection [50].
Relevant to Coronavirus pathogenesis, two studies of
contrasting IAV and SARS-CoV induced long [51] andsmall [52] non-coding RNAs were recently conducted
within a subset of the founder animals of the CC, focusing
on founder lines from the three genetically distant sub-
species of Mus musculus, which have distinct responses to
both SARS-CoV and IAV infection. Both of these studies
found that there were pervasive changes in the expression
levels of these noncoding transcripts during infections.
Importantly for systems genetics approaches, they
showed that these two pathogens led to differential
regulation of these noncoding RNAs and that the levels
Figure 3
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Platforms for Systems genetics discovery and validation. Traditionally, classical inbred strains such as C57BL/6J (a) have been used for systems
biology approaches. These classical systems have utilized (b) gene knockouts or (c) the introduction of functional changing mutations as perturbation/
validation systems. The Collaborative Cross (CC) and DO (DO) populations were derived from a set of eight genetically diverse founders whose
genomes are represented by the following colors (d): A/J (yellow), C57BL/6J (gray), 129s1/SvImJ (pink), NOD/ShiLtJ (dk. blue), NZO/HILtJ (lt. blue),
CAST/EiJ (green), PWK/PhJ (red), and WSB/EiJ (purple). CC lines (e) have inbred genomes that are mosaics of these eight founders (with the founder
contributions keeping the color coding of D). CC lines have well-characterized genomes and being inbred are an infinitely reproducible population.
Similarly (f) the Diversity Outbred (DO) is a completely outbred population of animals derived from the same eight founder strains. While this population
is not reproducible, the genetic architecture of the population can be reproduced. In these ways, both the CC and DO facilitate systems genetics
approaches. The CC and DO, by virtue of the large number of unique genomes, can be used (f) to create a variety of validation crosses, or sets of lines
with unique genetic combinations for further mechanistic study of polymorphisms of interest. Here, a panel of CC lines is being used to contrast the
PWK/PhJ (red) and 129S1/SvImJ (pink) alleles at Locus 1, while simultaneously being used to contrast A/J (yellow) and WSB/EiJ (purple) alleles at
Locus 2.of differential expression for these noncoding RNAs vary
depending on host genetic background. This work high-
lights that unique interactions between specific viral
infections and host genetic variation drive differential
disease outcomes, and through the use of systems
genetics approaches, host responses and the critical path-
ways causing various pathologic outcomes can be defined.With a growing appreciation for the overall roles of
noncoding RNAs in regulating immune responses and
pathogenesis [53], as well as evidence that polymorph-
isms within noncoding RNAs can directly impact patho-
logic outcomes during infection, such as clearance of
Hepatitis B infection [54], the investigation and detection
of noncoding RNAs in future systems genetics
approaches will provide a rich investigative environment
for investigating how host genetic variation shapes
immune responses and pathologic outcomes.
Future prospects
As illustrated throughout this study, the integration of
systems approaches in traditional studies on viral patho-
genesis provides immensely powerful tools with which to
identify the host factors critical for pathologic or protec-
tive outcomes following viral infections in experimental
systems. A key challenge for the field is to transition
targets generated by systems approaches into thera-
peutics and prophylactics. Recently this has been seen
for both MERS-CoV [55], and H7N9 avian influenza
[56], using cell culture models. In both cases, application
of systems approaches and contrasting infections (MERS-
CoV and SARS-CoV; H7N9 and H3N2 influenza) were
used to identify pathways differentially regulated be-
tween related pathogens, and then this information was
applied to select and test potential antiviral compounds
which were able to inhibit both the target and related
virus in the case of Coronaviruses [55], or just the
specific H7N9 target virus but not the related H3N2
virus [56]. Future approaches in these veins, and transi-
tioning such results to in vivo systems genetic platforms
such as the CC will further improve our capacity to
combat conventional and new viral diseases of the future.
A longstanding divide in the scientific community has
been bridging the gap between experimental systems and
human populations. Indeed, some commonalities exist
between murine and human immune responses [57,58],
such as the role of IFITM3 in both human and mouse
responses to influenza [58]. However, there are other
studies highlighting discordance between humans and
mice [59]. While systems approaches identify key genes,
both their focus on pathways and systemic responses, and
the explicit integration of genetic variation will allow for
more robust descriptions of how pathogens cause variant
disease responses within and across species. These results
will increase the likelihood that, while individual genes
might not be key regulators of disease across species,
there will be commonly identified pathways regulating
disease that can be identified in experimental models and
transitioned into human systems. In support of this hope,
Mitchell [21] was able to show common transcriptional
signatures between human cells and mice following
highly pathogenic flu and SARS infections. Similarly,
Sims [23] found conserved signals between immortalized
Calu3 cells and primary airway epithelial cultures.
Furthermore, systems based approaches studying influ-
enza vaccine responses within humans were able to
identify the CaMKIV kinase pathway as critical for these
responses, and this molecule was validated in murine
knockout systems [57]. The further advancement and
refinement of such approaches in experimental systems,
combined with state-of-the-art experimental approachessuch as gene editing [60], as well as molecular profiling
and disease data gathered from human cohorts [61], hold
keys for transitioning bench-top findings to clinical
results. Given the expanding nature of viral emergences,
due to increased connectivity and ease of travel, the
continuing refinement and further development of sys-
tems approaches combined with the advanced methodo-
logical approaches being developed should provide novel
avenues with which to quickly address the added com-
plexity of host genetic variation in combatting emerging
pathogens.
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